Currently out of the existing stock ratings of Serge Belanger, 347 are a BUY (90.13%), 38 are a HOLD (9.87%).

Serge Belanger

Work Performance Price Targets & Ratings Chart

Analyst Serge Belanger, currently employed at NEEDHAM, carries an average stock price target met ratio of 34.44% that have a potential upside of 57.95% achieved within 251 days.

Serge Belanger’s has documented 742 price targets and ratings displayed on 35 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CYTK, Cytokinetics at 01-Sep-2025.

Wall Street Analyst Serge Belanger

Analyst best performing recommendations are on GRAY (GRAYBUG VISION).
The best stock recommendation documented was for KALV (KALVISTA PHARMACEUTICALS) at 1/26/2021. The price target of $32 was fulfilled within 14 days with a profit of $15.65 (95.72%) receiving and performance score of 68.37.

Average potential price target upside

of $28.23 (70.98%) on PTX (PERNIX THERAPEUTICS HOLDINGS).
of $21.16 (52.29%) on CYTK (CYTOKINETICS).
of $16.6 (72.17%) on CLSD (CLEARSIDE BIOMEDICAL).

AMPH Amphastar P CLSD Clearside Biomedical COLL Collegium Pharmaceutical CORI Corium International FLXN Flexion Therapeutics HRTX Heron Therapeuti KALV Kalvista Pharmaceuticals LQDA Liquidia Technologies OMER Omeros PCRX Pacira Pharmaceuticals RVNC Revance The VRCA Verrica Pharmaceuticals ZGNX Zogenix AERI Aerie Pharmaceuticals AKBA Akebia Ther BCRX BioCryst Pharmaceuticals CRXT Clarus Therapeutics Holdings CYTK Cytokinetics GRAY Graybug Vision PHAS PhaseBio Pharmaceuticals TCDA Tricida TRVI Trevi Therapeutics XENE Xenon Pharmaceuticals ESPR Esperion Therapeutics PTX Pernix Therapeutics Holdings CRMD CorMedix AMAG AMAG Pharmaceuticals ARQT Arcutis Biotherapeutics EOLS Evolus VRDN Viridian Therapeutics ZYNE Zynerba Pharmaceuticals DICE Dice Molecules Holdings LLC MLTX MoonLake Immunotherapeutics NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares ALDR Alder BioPharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jason Gerberry (BAML)